Key points are not available for this paper at this time.
The existing suite of therapies for bone diseases largely act to prevent further bone loss but fail to stimulate healthy bone formation and repair. We describe an endogenous osteopeptide (PEPITEM) with anabolic osteogenic activity, regulating bone remodeling in health and disease. PEPITEM acts directly on osteoblasts through NCAM-1 signaling to promote their maturation and formation of new bone, leading to enhanced trabecular bone growth and strength. Simultaneously, PEPITEM stimulates an inhibitory paracrine loop: promoting osteoblast release of the decoy receptor osteoprotegerin, which sequesters RANKL, thereby limiting osteoclast activity and bone resorption. In disease models, PEPITEM therapy halts osteoporosis-induced bone loss and arthritis-induced bone damage in mice and stimulates new bone formation in osteoblasts derived from patient samples. Thus, PEPITEM offers an alternative therapeutic option in the management of diseases with excessive bone loss, promoting an endogenous anabolic pathway to induce bone remodeling and redress the imbalance in bone turnover.
Building similarity graph...
Analyzing shared references across papers
Loading...
Jonathan W. Lewis
University of Birmingham
Kathryn Frost
University of Birmingham
Georgiana Neag
Friedrich-Alexander-Universität Erlangen-Nürnberg
Cell Reports Medicine
University of Oxford
University of Birmingham
University Hospitals Birmingham NHS Foundation Trust
Building similarity graph...
Analyzing shared references across papers
Loading...
Lewis et al. (Wed,) studied this question.
synapsesocial.com/papers/68e6c02bb6db64358763f5c4 — DOI: https://doi.org/10.1016/j.xcrm.2024.101574